Spain

BMI View: While the healthcare cost-containment measures in the Royal Decree-Law 16/2012 in Spain do not include price cuts on medicines, we believe measures such as the new central... 2012-04-26

BMI View: Data that shows an 8.7% decline in public pharmaceutical expenditure will lead to drug companies questioning the economic viability of conducting business in Spain. This and... 2012-04-19

BMI View: The EUR6.37bn (US$6.88bn) Spanish public hospital debt situation will force the government to widen its cost-containment focus from price cuts on medicines to the implementation... 2012-03-22

BMI View: The EUR5.19bn Spanish public hospital debt situation will force the new government to widen its cost-containment focus from price cuts on medicines to the implementation of... 2012-02-15

BMI View: Reinforcing BMI's view that companies with significant exposure to debt-ridden European markets will be hard hit by government austerity measures across the region, and in... 2012-01-20

BMI Core View: Governments will increasingly impose price controls on pharmaceuticals. Drugmakers have generally charged what the market will bear in both developed and emerging markets.... 2012-01-04

BMI View: We believe the Spanish government's decision to implement further austerity measures is a necessary and prudent course of action. The country still has the third highest budget... 2012-01-03

BMI View: The delay in public hospital payments to drugmakers threatens Spain's attractiveness as a location in which to sell drugs and medical devices, especially as public health... 2011-10-11

BMI View: The delay in public hospital payments to drugmakers threatens Spain's attractiveness as a location in which to sell drugs and medical devices, especially as public health... 2011-10-11

BMI View: We believe the Spanish government's decision to implement further austerity measures is a necessary and prudent course of action. The country still has the third highest budget... 2011-07-25